Carlos I. Ponte-Negretti, Unidad de Medicina Cardiometabólica, Instituto Médico La Floresta, Caracas, Venezuela
Alberto Lorenzatti, Servicio de Cardiología, Fundación Rusculleda de Investigación en Medicina, Instituto Médico DAMIC, Córdoba, Argentina
Fernando Wyss-Quintana, Unidad de Cardiología Cardio Solutions, Ciudad de Guatemala, Guatemala
Rodrigo Alonso-K., Unidad Cardiovascular, Centro Avanzado de Medicina Metabólica y Nutrición, Santiago de Chile, Chile
Máxima Méndez-Castillo, Unidad de Lípidos, Clínica de lípidos CLI_LIPID, Santo Domingo, República Dominicana
Osiris Valdez-Tiburcio, Departamento de Cardiología, Hospital Central Romana, La Romana, República Dominicana
Vladimir E. Ullauri-Solórzano, Departamento de Cardiología, Hospital Metropolitano, Quito, Ecuador
Camila Y. Ullauri-Valcárcel, Unitat de Recerca, Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, España
Adriana Puente-Barragán, Departamento de Cardiología, Hospital Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México
Luz C. Zárate-Correa, Unidad de Cardiología, Cardiodec, Cali, Colombia
The current treatment of dyslipidemia in patients with cardiovascular risk is based on three well-defined principles: the primary therapeutic target is low-density lipoprotein cholesterol (LDL-C); therapeutic goals according to risk level should be achieved as early as possible; and drug combinations are increasingly necessary. Bempedoic acid (BA) is an orally administered prodrug selectively activated in hepatocytes that inhibits the enzyme adenosine triphosphate-citrate lyase, whose activity precedes that of HMG-CoA reductase in the cholesterol biosynthesis pathway.: An objective and cost-effective analysis of the role of BA in the therapeutic management of patients with dyslipidemia in Latin America was conducted along with a proposal for practical therapeutic algorithms. It is also a useful therapeutic tool to combine with statins and/or other non-statinic drugs to achieve LDL-C goals. As monotherapy, BA has been shown to significantly reduce major adverse cardiovascular events in patients who are statin-intolerant or unwilling to take statins. BA is an important therapeutic option for reducing LDL-C in patients with statin intolerance as well as in those who have not achieved LDL-C targets according to their cardiovascular risk. Its safety profile, clinical efficacy, and metabolic benefits position it as a valuable tool in the management of dyslipidaemia and in the prevention of atherosclerotic cardiovascular disease across diverse clinical settings.
Keywords: Bempedoic acid. LDL cholesterol. Dyslipidaemia. Cardiovascular prevention.